Business Context and Reporting Period
This Form 8-K was filed by Oramed Pharmaceuticals Inc. on August 18, 2019, reporting events occurring on August 5, 2019. The company is a biopharmaceutical entity focused on therapeutic candidates, with principal executive offices in New York and a wholly-owned Israeli subsidiary.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and appointments rather than financial performance.
Material Changes
The primary material change reported is the appointment of Mr. Joshua Hexter as Chief Operating & Business Officer, effective September 19, 2019. Mr. Hexter previously served as Chief Business Officer at BrainsWay Ltd. and held prior executive roles at Oramed and BioLineRx Ltd.
Management Commentary and Compensation
- Compensation Structure: Mr. Hexter's gross monthly salary is set at NIS 56,000, with the provision of a company car.
- Equity and Bonuses: He is eligible for bonuses and equity grants, with amounts to be determined at the discretion of the Board of Directors and the Compensation Committee.
- Agreements: The appointment is governed by an employment agreement with Oramed Ltd. (the Israeli subsidiary). The company expects to enter into a standard indemnification agreement with Mr. Hexter.
- Related Party Transactions: Other than his prior roles as an officer and consultant, Mr. Hexter is not a party to any transactions disclosable under Item 404 of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Mr. Hexter's appointment (September 19, 2019).
- Confirm the specific terms of the employment agreement with the Israeli subsidiary, Oramed Ltd.
- Monitor future filings for the specific amounts of bonuses and equity grants awarded to Mr. Hexter.
- Review the company's cash position to ensure liquidity supports the new executive compensation package.